Skip to main content
OpenTrials

Clinical trial condition

Bacterial Infections and Mycoses

Explore clinical trials studying Bacterial Infections and Mycoses. Study availability and eligibility vary by location and protocol.

5,905 public trials 636 recruiting studies
Refine in advanced search Browse all conditions

Bacterial Infections and Mycoses trial results

Completed

Safety & Immunogenicity Study of 10-Valent Pneumococcal Conjugate Vaccine When Administered as a 2-Dose Schedule

NCT00307034

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Gram-Positive Bacterial Infections, +4 more
Locations
  • GSK Investigational Site Hvidovre, Denmark
  • GSK Investigational Site Morvik, Norway
  • GSK Investigational Site Oslo, Norway
  • GSK Investigational Site Dolný Kubín, Slovakia
View Trial Details
Completed

Primary Vaccination Course in Children Receiving Pneumococcal Conjugate Vaccine GSK 1024850A or Prevenar™ and Hiberix™

NCT00680914

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Gram-Positive Bacterial Infections, +3 more
Locations
  • GSK Investigational Site Ansan, South Korea
  • GSK Investigational Site Bucheon-si, South Korea
  • GSK Investigational Site Daejeon, South Korea
  • GSK Investigational Site Gyeongnam, South Korea
View all 14 locations
View Trial Details
Completed

Immunogenicity and Safety of Meningococcal Vaccine GSK134612 vs. Menactra® in Healthy Adolescent/Adults Aged 10-25 Years.

NCT00454909

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Gram-Negative Bacterial Infections, +4 more
Locations
  • GSK Investigational Site Daly City, California, United States
  • GSK Investigational Site Fairfield, California, United States
  • GSK Investigational Site Redwood City, California, United States
  • GSK Investigational Site Sacramento, California, United States
View Trial Details
Completed

Primary Study to Demonstrate Non-inferiority and Immunogenicity of GSK Biologicals' Meningococcal Vaccine 134612

NCT00465816

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Gram-Negative Bacterial Infections, +4 more
Locations
  • GSK Investigational Site Aarhus N, Denmark
  • GSK Investigational Site Karlskrona, Sweden
  • GSK Investigational Site Linköping, Sweden
  • GSK Investigational Site Malmö, Sweden
View Trial Details
Completed

Safety of Purified Meningococcal Vaccine With Serogroups ACWY, in 3,000 Filipino Subjects Aged > 2 Years

NCT00290329

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Gram-Negative Bacterial Infections, +4 more
Locations
  • GSK Investigational Site Alabang, Muntinlupa City, Philippines
  • GSK Investigational Site Binangonan, Rizal, Philippines
  • GSK Investigational Site Cainta, Rizal, Philippines
  • GSK Investigational Site City of Muntinlupa, Philippines
View Trial Details
Completed

Safety & Immunogenicity of 1 Dose of GSK134612 in Children 12-14 Months and 3-5 Years Old

NCT00196976

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Gram-Negative Bacterial Infections, +4 more
Locations
  • GSK Investigational Site Eferding, Austria
  • GSK Investigational Site Graz, Austria
  • GSK Investigational Site Salzburg, Austria
  • GSK Investigational Site Vienna, Austria
View all 17 locations
View Trial Details

Related conditions